Carl Zeiss Meditec AG (SWX:AFX)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 2.78B -19.3% |
| Revenue (ttm) | 2.01B +0.1% |
| Net Income | 112.17M -19.1% |
| EPS | 1.29 -18.7% |
| Shares Out | n/a |
| PE Ratio | 24.83 |
| Forward PE | 24.23 |
| Dividend | 0.50 (1.57%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 32.00 |
| Day's Range | n/a |
| 52-Week Range | 21.48 - 32.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 10, 2026 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]
Financial Performance
In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.
Financial numbers in EUR Financial StatementsNews
Carl Zeiss Meditec Gets China Approval For PT LUNANA Myopia Lens
(RTTNews) - Carl Zeiss Meditec AG (AFX.DE) Monday reported that China's National Medical Products Administration (NMPA) approved its PT LUNANA phakic intraocular lens for myopia, or near-sightedness.
ZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lens
ZEISS Medical Technology showcased at CIIE its next-generation aspheric phakic intraocular lens (pIOL) PT LUNANA® to address myopia in China, a growing major public health challenge for the region.
EQS-AFR: Carl Zeiss Meditec AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Carl Zeiss Meditec AG / Preliminary announcement on the disclosure of financial statements Carl Zeiss Meditec AG: Preliminary announcement of the public...
Carl Zeiss Meditec AG - Depositary Receipt Price Target Decreased by 12.86% to $32.36
The average one-year price target for Carl Zeiss Meditec AG - Depositary Receipt (OTCPK:CZMWY) (DB:AFXA) has been revised to $32.36 / share. This is a decrease of 12.86% from the prior estimate of $37...
ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22,...
ZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAO
ZEISS Medical Technology will showcase its latest innovations and digital technologies at AAO, including: Connected cataract workflow – ZEISS VERACITY Surgery Planner reaches 3 million surgical cases ...
Carl Zeiss Meditec Q3 Earnings Call Highlights
Carl Zeiss Meditec ETR: AFX reported lower revenue and profitability for the first nine months of fiscal 2025/2026, as foreign-exchange effects, weakness in ophthalmology consumables and the suspensio...
Carl Zeiss Meditec AG Earnings Call Transcript: Q3 2026
Revenue and EBITDA declined year-over-year, mainly due to FX headwinds and weakness in APAC, especially in China’s ophthalmology segment. Strategic initiatives and cost-saving programs are underway, with guidance pointing to the lower end of the margin range for FY 2025/2026.
Carl Zeiss Meditec AG Quarterly report: Q3 2026
Carl Zeiss Meditec AG has published its Q3 2026 quarterly earnings report on August 6, 2026.
Carl Zeiss Meditec AG Slides: Q3 2026
Carl Zeiss Meditec AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 6, 2026.
Carl Zeiss Meditec AG Slides: Investor presentation
Carl Zeiss Meditec AG has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Carl Zeiss Meditec Q2 Earnings Call Highlights
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management po...
Carl Zeiss Meditec AG Earnings Call Transcript: Q2 2026
Six-month results showed revenue and margin declines due to currency headwinds and weak China IOL sales. The Profit Up Program targets over EUR 200 million in annual profit improvements by 2028/2029, with midterm EBITDA margin above 15% and a focus on operational efficiency and portfolio optimization.
Carl Zeiss Meditec AG Quarterly report: Q2 2026
Carl Zeiss Meditec AG has published its Q2 2026 quarterly earnings report on May 12, 2026.
Carl Zeiss Meditec AG Slides: Q2 2026
Carl Zeiss Meditec AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
Carl Zeiss Meditec AG Slides: Investor presentation
Carl Zeiss Meditec AG has posted slides in relation to its latest quarterly earnings report, which was published on February 12, 2026.
Carl Zeiss Meditec AG Earnings Call Transcript: Q1 2026
Revenue and profitability declined sharply year-over-year, driven by currency headwinds, weak sales in China and the US, and an unfavorable product mix. Regulatory uncertainty and intensified competition in China led to suspended guidance, with a significant one-off impact expected in Q2.
Carl Zeiss Meditec AG Quarterly report: Q1 2026
Carl Zeiss Meditec AG has published its Q1 2026 quarterly earnings report on February 12, 2026.
Carl Zeiss Meditec AG Slides: Q1 2026
Carl Zeiss Meditec AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 12, 2026.
Carl Zeiss Meditec AG Earnings Call Transcript: Q4 2025
Revenue grew 7.8% to EUR 2.23 billion with strong order entry and record recurring revenue. EBITDA margin improved to 11.6% despite FX and tariff headwinds. Guidance for 2025-2026 targets mid-single-digit revenue growth and a 12.5% EBITDA margin, with midterm ambitions of 16%-20% margin.
Carl Zeiss Meditec AG Annual report: Q4 2025
Carl Zeiss Meditec AG has published its Q4 2025 annual report on December 11, 2025.
Carl Zeiss Meditec AG Slides: Q4 2025
Carl Zeiss Meditec AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on December 11, 2025.
Carl Zeiss Meditec AG Slides: Investor Presentation
Carl Zeiss Meditec AG has posted slides in relation to its latest quarterly earnings report, which was published on August 8, 2025.
Carl Zeiss Meditec AG Earnings Call Transcript: Q3 2025
Order entry and revenue grew strongly, with recurring revenue at a record high and adjusted EBITDA margin improving. U.S. tariffs and FX headwinds weighed on net income, but product launches and D.O.R.C. integration supported growth. Guidance remains for moderate revenue growth and stable margins.
Carl Zeiss Meditec AG Quarterly report: Q3 2025
Carl Zeiss Meditec AG has published its Q3 2025 quarterly earnings report on August 7, 2025.